MLKL and chronic myelogenous leukemia, BCR-ABL1 positive: In contrast, a ribosomal inhibitor HHT [5], an alkaloid, also known as omacetaxine, used for treatment of chronic myelogenous leukemia [4, 16], strongly cooperated with MLKL KO in reducing clonogenic survival and the total number of DLD1 cells (Fig. 1E, F).